Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study (Q57252888)
Jump to navigation
Jump to search
scientific article published in 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study |
scientific article published in 2012 |
Statements
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study (English)
0 references
2012
0 references
107
0 references
03
0 references
584-589
0 references